Which has higher valuation & earnings, BSX or STE?

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boston Scientific $20.07B 3.10 $2.90B $2.47 17.41 STERIS $6.04B 3.41 $782.30M $8.18 25.81

Does the media prefer BSX or STE?

In the previous week, Boston Scientific had 30 more articles in the media than STERIS. MarketBeat recorded 33 mentions for Boston Scientific and 3 mentions for STERIS. STERIS's average media sentiment score of 1.06 beat Boston Scientific's score of 0.51 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 13 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive STERIS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EW or STE?

In the previous week, Edwards Lifesciences had 23 more articles in the media than STERIS. MarketBeat recorded 26 mentions for Edwards Lifesciences and 3 mentions for STERIS. STERIS's average media sentiment score of 1.06 beat Edwards Lifesciences' score of 0.75 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 10 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STE or BDX?

In the previous week, Becton, Dickinson and Company had 10 more articles in the media than STERIS. MarketBeat recorded 13 mentions for Becton, Dickinson and Company and 3 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.35 beat STERIS's score of 1.06 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 12 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STE or IDXX?

In the previous week, IDEXX Laboratories had 15 more articles in the media than STERIS. MarketBeat recorded 18 mentions for IDEXX Laboratories and 3 mentions for STERIS. IDEXX Laboratories' average media sentiment score of 1.13 beat STERIS's score of 1.06 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, DXCM or STE?

DexCom has higher earnings, but lower revenue than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.97B 6.31 $836.30M $2.53 32.82 STERIS $6.04B 3.41 $782.30M $8.18 25.81

Is DXCM or STE more profitable?

DexCom has a net margin of 20.12% compared to STERIS's net margin of 13.34%. DexCom's return on equity of 35.94% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% STERIS 13.34% 14.34% 9.66%

Does the media prefer DXCM or STE?

In the previous week, DexCom had 11 more articles in the media than STERIS. MarketBeat recorded 14 mentions for DexCom and 3 mentions for STERIS. STERIS's average media sentiment score of 1.06 beat DexCom's score of 0.89 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

STERIS (STE) Competitors

$211.10 -1.35 (-0.63%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$212.67 +1.57 (+0.74%)

As of 09/11/2026 07:44 PM Eastern

Compare

STE vs. BSX, EW, BDX, IDXX, and DXCM

Should you buy STERIS stock or one of its competitors? STERIS's main competitors and comparable companies include Boston Scientific (BSX), Edwards Lifesciences (EW), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), and DexCom (DXCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does STERIS compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Boston Scientific presently has a consensus target price of $71.46, indicating a potential upside of 66.20%. STERIS has a consensus target price of $271.33, indicating a potential upside of 28.53%. Given Boston Scientific's higher possible upside, equities research analysts plainly believe Boston Scientific is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.71
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Boston Scientific has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Boston Scientific had 30 more articles in the media than STERIS. MarketBeat recorded 33 mentions for Boston Scientific and 3 mentions for STERIS. STERIS's average media sentiment score of 1.06 beat Boston Scientific's score of 0.51 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	13 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Boston Scientific has a net margin of 17.50% compared to STERIS's net margin of 13.34%. Boston Scientific's return on equity of 19.28% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.50%	19.28%	10.89%
STERIS	13.34%	14.34%	9.66%

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.10	$2.90B	$2.47	17.41
STERIS	$6.04B	3.41	$782.30M	$8.18	25.81

Summary

Boston Scientific and STERIS tied by winning 8 of the 16 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Edwards Lifesciences has a net margin of 15.43% compared to STERIS's net margin of 13.34%. Edwards Lifesciences' return on equity of 15.68% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	15.43%	15.68%	12.05%
STERIS	13.34%	14.34%	9.66%

Edwards Lifesciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Edwards Lifesciences presently has a consensus price target of $100.27, indicating a potential upside of 18.61%. STERIS has a consensus price target of $271.33, indicating a potential upside of 28.53%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.74
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	8.02	$1.07B	$1.74	48.59
STERIS	$6.04B	3.41	$782.30M	$8.18	25.81

In the previous week, Edwards Lifesciences had 23 more articles in the media than STERIS. MarketBeat recorded 26 mentions for Edwards Lifesciences and 3 mentions for STERIS. STERIS's average media sentiment score of 1.06 beat Edwards Lifesciences' score of 0.75 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	10 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Edwards Lifesciences beats STERIS on 9 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

STERIS pays an annual dividend of $2.76 per share and has a dividend yield of 1.3%. Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.4%. STERIS pays out 33.7% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS has raised its dividend for 20 consecutive years and Becton, Dickinson and Company has raised its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a net margin of 13.34% compared to Becton, Dickinson and Company's net margin of 4.52%. Becton, Dickinson and Company's return on equity of 14.79% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.34%	14.34%	9.66%
Becton, Dickinson and Company	4.52%	14.79%	6.93%

94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$6.04B	3.41	$782.30M	$8.18	25.81
Becton, Dickinson and Company	$22.48B	2.18	$1.68B	$3.32	53.57

In the previous week, Becton, Dickinson and Company had 10 more articles in the media than STERIS. MarketBeat recorded 13 mentions for Becton, Dickinson and Company and 3 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.35 beat STERIS's score of 1.06 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	12 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS presently has a consensus target price of $271.33, suggesting a potential upside of 28.53%. Becton, Dickinson and Company has a consensus target price of $187.67, suggesting a potential upside of 5.52%. Given STERIS's stronger consensus rating and higher probable upside, equities analysts plainly believe STERIS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

STERIS has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Summary

STERIS beats Becton, Dickinson and Company on 10 of the 19 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

STERIS (NYSE:STE) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

STERIS currently has a consensus target price of $271.33, indicating a potential upside of 28.53%. IDEXX Laboratories has a consensus target price of $747.00, indicating a potential upside of 48.01%. Given IDEXX Laboratories' higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

IDEXX Laboratories has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$6.04B	3.41	$782.30M	$8.18	25.81
IDEXX Laboratories	$4.55B	8.73	$1.06B	$14.22	35.49

In the previous week, IDEXX Laboratories had 15 more articles in the media than STERIS. MarketBeat recorded 18 mentions for IDEXX Laboratories and 3 mentions for STERIS. IDEXX Laboratories' average media sentiment score of 1.13 beat STERIS's score of 1.06 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

STERIS has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

IDEXX Laboratories has a net margin of 25.03% compared to STERIS's net margin of 13.34%. IDEXX Laboratories' return on equity of 71.96% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.34%	14.34%	9.66%
IDEXX Laboratories	25.03%	71.96%	33.60%

Summary

IDEXX Laboratories beats STERIS on 12 of the 16 factors compared between the two stocks.

How does STERIS compare to DexCom?

DexCom (NASDAQ:DXCM) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DexCom currently has a consensus price target of $88.71, indicating a potential upside of 6.84%. STERIS has a consensus price target of $271.33, indicating a potential upside of 28.53%. Given STERIS's higher probable upside, analysts plainly believe STERIS is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, DexCom had 11 more articles in the media than STERIS. MarketBeat recorded 14 mentions for DexCom and 3 mentions for STERIS. STERIS's average media sentiment score of 1.06 beat DexCom's score of 0.89 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, STERIS has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

DexCom has a net margin of 20.12% compared to STERIS's net margin of 13.34%. DexCom's return on equity of 35.94% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
STERIS	13.34%	14.34%	9.66%

DexCom has higher earnings, but lower revenue than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82
STERIS	$6.04B	3.41	$782.30M	$8.18	25.81

Summary

DexCom beats STERIS on 12 of the 17 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STE vs. The Competition

Export

Metric	STERIS	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$20.71B	$5.38B	$7.13B	$23.17B
Dividend Yield	1.28%	1.79%	2.56%	3.56%
P/E Ratio	25.81	25.09	275.24	28.71
Price / Sales	3.41	82.90	656.02	94.44
Price / Cash	13.98	32.53	77.04	33.82
Price / Book	2.88	5.97	10.33	4.74
Net Income	$782.30M	$150.75M	$3.50B	$1.07B
7 Day Performance	-6.01%	-2.83%	-3.32%	-2.00%
1 Month Performance	-10.65%	-3.09%	-0.41%	-2.69%
1 Year Performance	-15.59%	9.34%	19.21%	10.45%

STERIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STE STERIS	4.7324 of 5 stars	$211.10 -0.6%	$271.33 +28.5%	-16.3%	$20.71B	$6.04B	25.81	17,937	Positive News
BSX Boston Scientific	4.8797 of 5 stars	$47.85 +0.1%	$71.62 +49.7%	-58.8%	$69.27B	$20.07B	19.37	59,000	Analyst Forecast Short Interest Increase
EW Edwards Lifesciences	4.3557 of 5 stars	$90.00 +0.1%	$100.27 +11.4%	+8.4%	$51.76B	$6.07B	51.72	16,000	Trending News Analyst Forecast
BDX Becton, Dickinson and Company	3.659 of 5 stars	$184.78 +0.0%	$187.67 +1.6%	-6.7%	$50.90B	$21.84B	55.66	72,000	Positive News
IDXX IDEXX Laboratories	4.1959 of 5 stars	$535.38 flat	$747.00 +39.5%	-21.8%	$42.18B	$4.30B	37.65	11,000	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Competitors

STE vs. BSX, EW, BDX, IDXX, and DXCM

How does STERIS compare to Boston Scientific?

Summary

How does STERIS compare to Edwards Lifesciences?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Summary

How does STERIS compare to IDEXX Laboratories?

Summary

How does STERIS compare to DexCom?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Competitors

STE vs. BSX, EW, BDX, IDXX, and DXCM

How does STERIS compare to Boston Scientific?

Do analysts recommend BSX or STE?

Which has more risk and volatility, BSX or STE?

Do insiders and institutionals believe in BSX or STE?

Does the media prefer BSX or STE?

Is BSX or STE more profitable?

Which has higher valuation & earnings, BSX or STE?

Summary

How does STERIS compare to Edwards Lifesciences?

Is EW or STE more profitable?

Which has more risk and volatility, EW or STE?

Do analysts prefer EW or STE?

Which has preferable earnings & valuation, EW or STE?

Does the media refer more to EW or STE?

Do insiders & institutionals hold more shares of EW or STE?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Is STE or BDX a better dividend stock?

Is STE or BDX more profitable?

Do institutionals & insiders have more ownership in STE or BDX?

Which has higher earnings and valuation, STE or BDX?

Does the media refer more to STE or BDX?

Do analysts rate STE or BDX?

Which has more risk and volatility, STE or BDX?

Summary

How does STERIS compare to IDEXX Laboratories?

Do analysts rate STE or IDXX?

Which has stronger earnings & valuation, STE or IDXX?

Does the media favor STE or IDXX?

Do insiders & institutionals believe in STE or IDXX?

Which has more risk and volatility, STE or IDXX?

Is STE or IDXX more profitable?

Summary

How does STERIS compare to DexCom?

Do insiders and institutionals believe in DXCM or STE?

Do analysts rate DXCM or STE?

Does the media prefer DXCM or STE?

Which has more volatility and risk, DXCM or STE?

Is DXCM or STE more profitable?

Which has preferable earnings & valuation, DXCM or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools